Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The VALUE trial: a commentary.

Peter Sever

    Journal of the Renin-Angiotensin-Aldosterone System : JRAAS
    |November 5, 2004
    PubMed
    Summary
    This summary is machine-generated.

    The VALUE trial found that amlodipine, a calcium channel blocker, was associated with fewer heart attacks and strokes compared to valsartan, an angiotensin receptor blocker. Blood pressure control was the key factor in patient outcomes.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Long-term blood pressure variability: an emerging cardiovascular risk factor.

    The British journal of cardiology·2026
    Same author

    The impact of blood pressure variability on cardiovascular and renal outcomes in patients with and without diabetes: insights from the Anglo-Scandinavian Cardiac Outcomes Trial.

    Journal of hypertension·2025
    Same author

    Blood pressure variability: a review.

    Journal of hypertension·2025
    Same author

    Polygenic prediction of body mass index and obesity through the life course and across ancestries.

    Nature medicine·2025
    Same author

    '4 Ss' for successful blood pressure control.

    Journal of hypertension·2025
    Same author

    The relationship of baseline high-sensitivity C-reactive protein with incident cardiovascular events and all-cause mortality over 20 years.

    EBioMedicine·2025
    Same journal

    Relationship between Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism and the Risk of COVID-19: A Meta-Analysis.

    Journal of the renin-angiotensin-aldosterone system : JRAAS·2023
    Same journal

    Timing Matters: Effects of Early and Late Estrogen Replacement Therapy on Glucose Metabolism and Vascular Reactivity in Ovariectomized Aged Wistar Rats.

    Journal of the renin-angiotensin-aldosterone system : JRAAS·2023
    Same journal

    Genetic Variants Associated with High Susceptibility of Premature Ischemic Stroke.

    Journal of the renin-angiotensin-aldosterone system : JRAAS·2023
    Same journal

    Renin Trajectories and Outcome in Stable Heart Failure with Reduced Ejection Fraction (HFrEF) on Contemporary Therapy: A Monocentric Study from an Austrian Tertiary Hospital Outpatient Clinic.

    Journal of the renin-angiotensin-aldosterone system : JRAAS·2023
    Same journal

    New Viral Diseases and New Possible Remedies by Means of the Pharmacology of the Renin-Angiotensin System.

    Journal of the renin-angiotensin-aldosterone system : JRAAS·2023
    Same journal

    Angiotensin-Converting Enzyme and Hypertension: A Systemic Analysis of Various ACE Inhibitors, Their Side Effects, and Bioactive Peptides as a Putative Therapy for Hypertension.

    Journal of the renin-angiotensin-aldosterone system : JRAAS·2023
    See all related articles

    Area of Science:

    • Cardiology
    • Pharmacology
    • Hypertension Research

    Background:

    • The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial investigated two antihypertensive strategies: valsartan (angiotensin receptor blocker) versus amlodipine (calcium channel blocker).
    • Diuretics were added as needed to achieve blood pressure goals in over 15,000 patients over 4.2 years.
    • The study aimed to compare coronary heart disease outcomes between the two treatment groups.

    Discussion:

    • While the primary composite endpoint for cardiac morbidity and mortality showed no significant difference, amlodipine demonstrated a statistically significant reduction in myocardial infarction and a trend towards reduced stroke events compared to valsartan.
    • A non-significant increase in hospitalised heart failure was observed with amlodipine.
    • Early achievement of lower blood pressure levels in the amlodipine group likely contributed to its observed benefits.

    Related Experiment Videos

    Key Insights:

    • Lowering blood pressure is the primary determinant of outcomes in antihypertensive therapy trials.
    • Valsartan treatment was associated with a lower incidence of new-onset diabetes compared to amlodipine.
    • Amlodipine showed a potential benefit in reducing cardiovascular events like myocardial infarction and stroke.

    Outlook:

    • Further research could explore the long-term impact of these antihypertensive strategies on specific cardiovascular endpoints and diabetes incidence.
    • The findings underscore the importance of individualized treatment approaches in hypertension management.
    • Future trials may focus on optimizing combination therapies to maximize benefits and minimize risks.